AnaptysBio, Inc. reported earnings results for the fourth quarter ended December 31, 2023. For the fourth quarter, the company reported net loss was USD 42.21 million compared to USD 26.41 million a year ago. Basic loss per share from continuing operations was USD 1.59 compared to USD 0.93 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
24.34 USD | +14.27% | +26.90% | +13.63% |
Apr. 16 | Leerink Partners Starts AnaptysBio With Outperform Rating, $47 Price Target | MT |
Apr. 11 | Wells Fargo Initiates AnaptysBio With Overweight Rating, $56 Price Target | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+13.63% | 582M | |
-3.46% | 102B | |
+1.41% | 96.29B | |
+2.13% | 22.18B | |
-15.84% | 21.2B | |
-9.21% | 18.31B | |
-39.98% | 17.38B | |
-14.65% | 16.36B | |
+4.39% | 13.97B | |
+31.35% | 12.17B |
- Stock Market
- Equities
- ANAB Stock
- News AnaptysBio, Inc.
- AnaptysBio, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023